Below are the most recent publications written about "Receptors, IgG" by people in Profiles.
-
Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, Yu L, Butchar JP, Tridandapani S, Croce CM, Caligiuri MA. miR-155 regulates IFN-? production in natural killer cells. Blood. 2012 Apr 12; 119(15):3478-85.
-
Stolla M, Stefanini L, André P, Ouellette TD, Reilly MP, McKenzie SE, Bergmeier W. CalDAG-GEFI deficiency protects mice in a novel model of Fc? RIIA-mediated thrombosis and thrombocytopenia. Blood. 2011 Jul 28; 118(4):1113-20.
-
Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011 Jun 01; 117(11):2442-51.
-
Reilly MP, Sinha U, André P, Taylor SM, Pak Y, Deguzman FR, Nanda N, Pandey A, Stolla M, Bergmeier W, McKenzie SE. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood. 2011 Feb 17; 117(7):2241-6.
-
Crow AR, Song S, Suppa SJ, Ma S, Reilly MP, Andre P, McKenzie SE, Lazarus AH. Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP? Blood. 2011 Jan 20; 117(3):971-4.
-
Flores M, Desai DD, Downie M, Liang B, Reilly MP, McKenzie SE, Clynes R. Dominant expression of the inhibitory FcgammaRIIB prevents antigen presentation by murine plasmacytoid dendritic cells. J Immunol. 2009 Dec 1; 183(11):7129-39.
-
Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol. 2008 Sep 15; 181(6):3784-92.
-
Schirmer DA, Song SC, Baliff JP, Harbers SO, Clynes RA, Krop-Watorek A, Halverson GR, Czerwinski M, Spitalnik SL. Mouse models of IgG- and IgM-mediated hemolysis. Blood. 2007 Apr 1; 109(7):3099-107.
-
Rahman ZS, Alabyev B, Manser T. FcgammaRIIB regulates autoreactive primary antibody-forming cell, but not germinal center B cell, activity. J Immunol. 2007 Jan 15; 178(2):897-907.
-
Khan KD, Emmanouilides C, Benson DM, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res. 2006 Dec 01; 12(23):7046-53.